Today’s Research Reports on Trending Tickers: AbbVie and Intercept Pharmaceuticals
All three major indexes reached record highs Tuesday as investor’s concerns over rising geopolitical tensions and damage from hurricanes have subsided. The Dow Jones Industrial Average gained 0.28 percent to close at a record 22,118.86, while the S&P 500 Index increased 0.34 percent to close at a record 2,496.48. The Nasdaq Composite Index also rose 0.34 percent to close at a record 6,454.28. Financial stocks spiked Tuesday as the benchmark 10-year Treasury yield rallied to close at 2.171 percent. The Financial Select Sector SPDR Fund exchange-traded fund gained 1.1 percent on Tuesday.
“As long as these two issues – North Korea and the hurricane – have receded as concerns, it gives investors a green light to focus on stronger fundamentals,” said David Joy, chief market strategist at Ameriprise Financial in Boston.
RDI Initiates Coverage on:
Intercept Pharmaceuticals Inc.
AbbVie’s stock edged 0.86% higher Tuesday, to close the day at $87.75. The stock recorded a trading volume of 11,155,613 shares, which was above its three months average volume of 5,463,290 shares. In the last year AbbVie’s shares have traded in a range of 55.06 – 87.97. The share price has gained 59.37% from its 52 week low. The company’s shares are currently trading above their 200-day moving average. Moreover, the stock’s 50-day moving average of $73.09 is greater than its 200-day moving average of $68.79. Shares of AbbVie are trading at a Price to Earnings ratio of 21.58. Shares of AbbVie have gained approximately 40.13 percent year-to-date.
Access RDI’s AbbVie Inc. Research Report at:
On Tuesday, shares in Intercept Pharmaceuticals recorded a trading volume of 5,915,396 shares, which was above the three months average volume of 420,922 shares. The stock ended the day 13.54% lower at 98.12. The stock is currently trading 43.27% below its 52 week high with a 52 week trading range of 90.53 – 172.95.The company’s shares are currently trading below their 200-day moving average. Moreover, the stock’s 50-day moving average of $112.60 is below its 200-day moving average of $117.12. Shares of Intercept Pharmaceuticals have fallen approximately 9.69 percent year-to-date.
Access RDI’s Intercept Pharmaceuticals Inc. Research Report at:
Our Actionable Research on AbbVie Inc. (NYSE:ABBV) and Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.